Hayato Watanabe
Seminars
Wednesday 19th November 2025
PureCap: Demonstrating an Ultra-Pure Next-Generation mRNA Cap Analog with Significantly Improved Potency Profile
11:30 am
- The development of high quality mRNA vaccines and therapeutics hinges on the optimization of mRNA synthesis, particularly the capping process. PureCap is a nextgeneration mRNA cap analog designed to address key challenges in the field: purity, potency, and scalability
- Utilizing a photo-labile cap to deliver an ultra pure fully capped, fully functional mRNA product with significantly reduced levels of double stranded RNA and minimizing unwanted immune activation and enhancing safety profiles
- Illustrating PureCap as a promising solution for enhancing the performance of mRNAbased therapies and vaccines, improving both efficacy and safety at an industrial scale
